Relay Therapeutics, Inc. SEC filings RLAY

Relay Therapeutics, Inc. has 556 filings in SEC EDGAR's recent list, going back to May 22, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Relay Therapeutics, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 9, 2026
PRE 14A Preliminary proxy statement Apr 16, 2026 Jun 9, 2026
DEFA14A Additional proxy material Apr 23, 2025 —
DEF 14A Proxy statement Apr 23, 2025 Jun 6, 2025
DEFA14A Additional proxy material Apr 23, 2024 —
DEF 14A Proxy statement Apr 23, 2024 Jun 3, 2024
DEFA14A Additional proxy material Apr 21, 2023 —
DEF 14A Proxy statement Apr 21, 2023 —
DEFA14A Additional proxy material Apr 14, 2022 —
DEF 14A Proxy statement Apr 14, 2022 May 27, 2022
PRE 14A Preliminary proxy statement Apr 1, 2022 May 27, 2022
DEFA14A Additional proxy material Apr 7, 2021 —
DEF 14A Proxy statement Apr 7, 2021 May 19, 2021

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
RLAY (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Large accelerated filer
SEC CIK
1812364

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.